OpenAI Leaps Beyond U.S. Borders With Strategic Israeli Hospital Partnership for Clinical AI
Sheba Medical Center gains exclusive international access to ChatGPT Health, positioning Israel as OpenAI's testing ground for global healthcare expansion.

OpenAI has made its first major international move in healthcare, selecting Israel's Sheba Medical Center as its inaugural hospital partner outside the United States. The partnership grants Sheba early access to ChatGPT Health and other clinical AI models that have been restricted to a select group of American hospitals since their January 2025 launch.
The strategic collaboration, brokered through Sheba's ARC innovation center and OpenAI's Head of Health Nate Gross, signals the company's intent to expand its healthcare footprint globally while testing its clinical decision support tools in diverse medical environments. For Sheba, the agreement offers a rare opportunity to shape product development and customize OpenAI's foundation models with institutional protocols before broader market release.
What Sheba Gains From Early Access
The partnership provides Sheba physicians with access to ChatGPT Health models designed specifically for clinical workflows. These tools deliver medical literature citations, supporting studies, journal references, and publication dates to assist with diagnostic and treatment decisions—all within an encrypted system built to meet healthcare security requirements.
Beyond simple access, Sheba will integrate its own clinical protocols, treatment pathways, and institutional guidelines directly into OpenAI's models. This customization capability allows the hospital to create AI tools that reflect its specific standards of care while maintaining the reasoning capabilities of large language models. A Sheba delegation is scheduled to visit OpenAI headquarters in August 2026 for executive meetings to advance this integration work.
The Israeli medical center already operates an extensive AI portfolio, including Aidoc for medical imaging analysis and SmartER for emergency department documentation. The OpenAI partnership adds clinical decision support to this ecosystem, potentially creating synergies across diagnostic imaging, documentation, and treatment planning workflows.
Strategic Implications for the Clinical AI Market
OpenAI's expansion through strategic hospital partnerships rather than broad commercial release reveals a deliberate approach to healthcare market entry. By selecting a prominent international academic medical center with established innovation infrastructure—Sheba's ARC center was founded in 2019 by Prof. Yitshak Kreiss and Dr. Eyal Zimlichman—OpenAI gains credibility and real-world testing data while controlling its exposure to regulatory and clinical risk.
This model intensifies competition in the clinical decision support market, where established vendors like Epic Systems, Microsoft's Nuance, and specialized AI companies have built integration advantages with electronic health records. OpenAI's approach of allowing hospitals to embed institutional protocols into foundation models may become a key differentiator, offering customization depth that rigid, pre-trained systems cannot match.
For competitors, the partnership demonstrates how foundation model providers are moving aggressively into healthcare verticals previously dominated by specialized clinical AI vendors. Companies like Aidoc—already deployed at Sheba—now face the prospect of competing alongside or against the same foundation models that power consumer AI applications.
The Patient Impact Question
While the technology promises improved diagnostic accuracy and treatment consistency through evidence-based citations, the actual clinical outcomes remain to be demonstrated. The partnership's value will ultimately be measured not in documentation efficiency or workflow optimization, but in whether AI-assisted decisions translate to better patient outcomes, reduced diagnostic errors, and more equitable care delivery.
As OpenAI scales internationally through partnerships like Sheba, the healthcare industry will be watching closely to see whether large language models can deliver on their clinical promise or simply add another layer of technology to already complex care workflows.
Sources
Companies in this article
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.